CRISPR 2.0? What You Need to Know About Base Editing

Base-editing technology is a new generation of gene-editing tools that allow the precise editing of single-point mutations without generating double-stranded DNA breaks as CRISPR-Cas9 does. Base editing overcomes several limitations of CRISPR/Cas9 and offers a new way to reverse disease-causing mutations and potentially cure thousands of genetic diseases. Base editing, which was built upon CRISPR/Cas9, has been dubbed as ‘CRISPR2.0’. In this video, we are going to learn about David Liu, the inventor of base editing, and the company he co-founded, BEAM therapeutics (BEAM). BEAM is a stock that Cathy Wood has been keeping adding to her fund. What makes BEAM so unique when compared to other gene-editing companies? And what future can we envision with base editing?

#BaseEditing
#BEAM
#CathyWood
#ARKG
#GeneticDiseases
#DavidLiu
#CRISPR
#GeneEditing
#BiotechInvestor

Other Videos:
How Does Merck’s Antiviral Pill Molnupiravir Work to Fight COVID-19? Molecular Mechanism Explained!
   • How Does Merck’s Antiviral Pill Molnu...  

The Science Behind Pfizer’s Oral COVID-19 Pill (Paxlovid) – HOW DOES IT WORK?
   • Видео  

Base Editing Enters the Clinic – JUST 6 Years After its Invention!!!
   • Base Editing Enters the Clinic – JUST...  

Can We Combine the Power of CRISPR and CAR-T to Fight CANCER? Caribou (#CRBU) is Doing Just that!!!
   • Can We Combine the Power of CRISPR an...  

CRISPR for the HEART? Why VERVE Therapeutics’ Cardiovascular Plan can be MASSIVE & LIFE-SAVING?!!
   • CRISPR for the HEART? Why VERVE Thera...  

Can CRISPR Cure Blindness? Science Fiction or Medical Breakthrough? Why EDIT Stock is CRASHING!!!
   • Can CRISPR Cure Blindness? Science Fi...  

Will Intellia Therapeutics (NTLA) become Cathy Wood's next Tesla (TSLA)? | NTLA-2001
   • Will Intellia Therapeutics (NTLA) bec...  

Can CRISPR Therapeutics (CRSP) deliver a ONE TIME CURE for genetics diseases? | CTX001
   • Can CRISPR Therapeutics (CRSP) delive...  

References
Beam Therapeutics
https://beamtx.com/

Beam Therapeutics Q2 Financial Results
https://investors.beamtx.com/news-rel...

Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
https://www.nature.com/articles/natur...

David Liu’s TED Talk: Can we cure genetic diseases by rewriting DNA?
https://www.ted.com/talks/david_r_liu...

Base Editing Animation (from CRISPR: Gene editing and beyond)
   • CRISPR: Gene editing and beyond  

Broad researcher David Liu describes the power of single-letter base editing
   • Broad researcher David Liu describes ...  

Video: Base editing successfully treats progeria in mice
   • Base editing successfully treats prog...  

In vivo adenine base editing rescues Hutchinson-Gilford progeria syndrome
https://www.nature.com/articles/s4158...

ARK Invest Podcast: Therapeutic Human Gene Editing with Dr. David Liu
https://ark-invest.com/podcast/ep106-...

***Disclaimer
I (Biotech Investor) hold a Ph.D. degree in life science and conducted 5 years of postdoctoral training in molecular biophysics at UC Berkeley. I am currently a full-time employee of a clinical-stage biopharmaceutical company, conducting early-stage drug discovery research. I have no professional affiliation with any of the companies or stocks discussed on this channel. This video is strictly for educational and entertainment purposes, and none of the contents in the video are for medical or financial/investment advice. I have no obligation to update, change or correct any information described in this video as news and stock prices change. The thoughts described in this channel are my own and do not reflect the company that I work for. This is not a solicitation to invest in any company I discussed in this channel, and I am not a financial or medical advisor. Investment involves risks and past performance should not be used as a gauge for future success. Seek a financial advisor to determine the appropriate investment strategies for your given circumstances. Investors should obtain their own independent financial advice and understand the risks associated with investment products/ services before making investment decisions.